Asset

  • No.

    112

  • Asset Title

    Engineered Tolerogenic Artificial Antigen-presenting Cells for Specific Expansion of Regulatory T Cells

  • Organization

    Johns Hopkins University

  • Product Type

    Cell therapy

  • Therapeutic Area

    Immunology

  • Development Stage

    Hit To Lead or Lead Optimization

  • Technical Summary

    • A biodegradable particle comprising a polyester or polyester blend, a first protein that binds to an immune cell, and a second protein that promotes proliferation and / or activation of immune cells, and a third soluble protein or small molecule encapsulated within the particle. The second protein is a fusion protein comprising at least a portion of an antibody and at least a portion of a Cytokine.

    • Tolerogenic antigen presenting cells (TolAPCs) consisting of a biodegradable particle surface-conjugated with a combination of IC and autoantigen-loaded MHC tetramers have been developed. 

    • TolAPCs are synthesized by forming a polymer core and covalently attaching ICs and specific autoantigen complexes to the surface. To evaluate performance, TolAPCs were incubated in-vitro with CD4+ T cells and compared to free IL-2 cytokine and free IC complexes. 

    • TolAPCs selectively stimulated Treg populations and achieved the same stimulation as free IC and greater stimulation than free IL-2. In an in-vivo mouse model, TolAPCs also increased the ratio of Treg cells compared to a no treatment condition. 

    • Altogether, the inventors have demonstrated efficacy of TolAPCs as an antigen specific IC based regulatory T cell modulator. 

  • Patent

    US20220160891A1

  • Publication

    Biomimetic tolerogenic artificial antigen presenting cells for regulatory T cell induction. Acta Biomater. (2020)

  • Attachment

TOP